SP-471P is a potent inhibitor of dengue virus (DENV) protease, exhibiting half-maximal effective concentrations (EC50) of 5.9 μM for DENV1, 1.4 μM for DENV2, 5.1 μM for DENV3, and 1.7 μM for DENV4, with a cytotoxic concentration (CC50) greater than 100 μM. Additionally, SP-471P effectively reduces DENV viral RNA synthesis [1].

SP-471P demonstrates low micromolar potency against DENV1, DENV2, DENV3, and DENV4, with EC50 values of 5.9 μM, 1.4 μM, 5.1 μM, and 1.7 μM, respectively [1]. At a concentration of 10 μM and an incubation period of 48 hours, it achieves an EC50 of 1.5 μM against ADE infection in human peripheral blood mononuclear cells [1]. Additionally, at the same concentration over a 6-54 hour period, it diminishes viral RNA synthesis in DENV2 [1], and at 30 hours post-treatment, SP-471P targets the NS3 int cleavage site in DENV2-infected Huh7 cells [1].